Scan: FDA approves Retatrutide this year?

1. Planner Fable 5.1 · Fermi decomposition + tool plan

Tools chosen: polymarket_direct claude_news article_search gdelt_news polymarket_related kalshi_related earnings_data wikipedia

Sub-questions (Fermi decomposition)

What is Lilly's most recently stated timeline for retatrutide Phase 3 (TRIUMPH) topline data and NDA submission — have any TRIUMPH trials read out yet?
Has Lilly publicly guided to a regulatory submission date for retatrutide, and would a standard (10-month) or priority (6-month) review complete before Dec 31, 2026?
Has retatrutide received or been discussed for any expedited pathway (priority review voucher, Commissioner's National Priority Voucher, Fast Track, Breakthrough) that could shorten FDA review?
What is the base rate/timeline from NDA submission to approval for recent GLP-1-class obesity drugs (tirzepatide, orforglipron, semaglutide) at FDA?
Are there safety signals (e.g., heart rate, arrhythmia) or trial delays reported for retatrutide that could push filing or trigger a CRL?
What do Lilly's earnings calls and investor guidance say about retatrutide's expected launch year (2026 vs 2027)?

Planner reasoning

Retatrutide is in Phase 3 (TRIUMPH program) with topline readouts expected through 2025-2026; FDA approval by end of 2026 requires an NDA filing plus a ~6-10 month review (priority review or a Commissioner's National Priority Voucher could compress this). The key drivers are Lilly's stated filing timeline, whether Phase 3 data has read out, and any expedited review pathway. Start with the Polymarket price as anchor, then gather news on trial timelines and regulatory submission plans.

2. Research Parallel tool calls

tool	status	time	items	summary
polymarket_direct	OK	0.6s	1	## This Market's Polymarket Data FDA approves Retatrutide this year? - Current price (probability): 11.70% - 7-day price change: +8.50% - 30-day price change: +8.75% - Total volume: $581,202 (USD notional) - Price range: 1.55% - 15.50% - Data points: 90 days
claude_news	OK	29.1s	13	Based on the latest available information (as of September 2026): - Phase 3 TRIUMPH program still reporting through 2026: TRIUMPH-4 (obesity/knee osteoarthritis) reported first, in Dec 2025; TRIUMPH-1 (pivotal obesity) topline came May 21, 2026 showing at 80 weeks, participants on 4mg of retat
article_search	OK	4.5s	24	Fetched 24 unique articles across 4 queries (lookback=120d). 'retatrutide Phase 3 TRIUMPH results': 10 articles \| 'retatrutide FDA submission timeline Eli Lilly': 10 articles \| 'retatrutide approval 2026': 10 articles \| 'Eli Lilly orforglipron priority voucher FDA approval timeline': 10 articles
gdelt_news	OK	82.1s	20	GDELT: 20 articles across 2 queries (lookback=60d). 'retatrutide': 10 hits \| 'Eli Lilly retatrutide FDA': 10 hits
polymarket_related	OK	4.1s	0	Scanned 100 active Polymarket markets, kept 0 matches. keyword 'retatrutide': 0 markets \| keyword 'FDA approves': 0 markets \| keyword 'orforglipron': 0 markets \| keyword 'Eli Lilly': 0 markets
kalshi_related	OK	3.9s	2	2 related markets / summaries. keyword 'retatrutide': no matches \| keyword 'FDA approval': ok \| keyword 'Eli Lilly': ok
earnings_data	OK	0.2s	1	Fetched FMP data for 1 ticker(s).
wikipedia	OK	0.2s	3	Fetched 3 Wikipedia entries (0 missing pages).

3. Evidence Brief Sonnet 5 · 7276 chars

# Current state Lilly confirmed on 2026-07-23 that it will file a BLA (not NDA) for retatrutide in Q1 2027, a delay from earlier guidance pointing to a late-2026 submission. Since the FDA review clock has not started, standard-track approval by Dec 31, 2026 is essentially foreclosed even under priority review. Polymarket prices this outcome at 11.7% (rising), reflecting residual tail-risk/uncertainty pricing rather than base-case expectation. # Timeline of key events - 2025-12: TRIUMPH-4 (obesity/knee osteoarthritis) topline reported first among Phase 3 trials (confirmed, claude_news). - 2026-05-21: TRIUMPH-1 (pivotal obesity trial) topline reported — 17.6-25.0% weight loss across doses vs 3.9% placebo at 80 weeks (confirmed, CNBC/Pharmaceutical Journal). - 2026-07-09: Lilly (per CNBC) states it "expects to submit the triple-G drug for FDA approval later this year" (2026) — earlier guidance (confirmed reported). - 2026-07-23: TRIUMPH-2 and TRIUMPH-3 toplines reported (up to 20.8%/22.6% weight loss); Lilly announces BLA filing now targeted for Q1 2027, not 2026, citing need for more manufacturing/quality-control data (confirmed, CNBC/AJMC/BioPharma Dive). - 2026-08-04/07: Lilly opens early/pre-approval access program for retatrutide to some patients ahead of formal approval (confirmed, Yahoo/Fox). - 2026-08-14/26: Lilly sues six companies over unauthorized retatrutide sales amid black-market activity, underscoring drug remains unapproved (confirmed, Healio/Fool). - 2026-09-04: BBC reports base-rate context: only ~50% of Phase III drugs are ultimately FDA-approved (reported). # Event Will the FDA approve retatrutide (Eli Lilly) — full or conditional, any indication — between market creation and Dec 31, 2026? # Outcomes to forecast - Yes - No # Kalshi market anchor No direct Kalshi price returned for this ticker in raw research; Polymarket equivalent market shows YES at 11.7%, up +8.5% (7d) and +8.75% (30d), range 1.55%–15.5% over 90 days, volume $581K. This uptrend likely reflects positive Phase 3 data (TRIUMPH-2/3) rather than any regulatory acceleration, since the same period saw the submission timeline pushed back. Treat 11.7% as the consensus prior to beat, likely still too high given confirmed Q1 2027 filing. # Sub-question answers 1. **TRIUMPH readouts/NDA timeline**: All five TRIUMPH trials have reported positive Phase 3 data as of July 2026 (TRIUMPH-1: May 21; TRIUMPH-2/3: July 23; TRIUMPH-4: Dec 2025). Lilly now targets BLA submission Q1 2027, not NDA — retatrutide is regulated as a biologic (claude_news, CNBC, AJMC). 2. **Submission date & review length**: Lilly's own guidance (2026-07-23) is Q1 2027 BLA filing. Standard review is 10-12 months, priority ~6 months; even priority review starting Q1 2027 lands mid-2027 at earliest — after the Dec 31, 2026 close (retaweightloss.com, claude_news). 3. **Expedited pathway status**: No confirmed grant of Fast Track/Breakthrough/Priority Review Voucher/Commissioner's National Priority Voucher found in research. Whether FDA will grant priority review "has not yet been determined" (retaweightloss.com). 4. **Base rate for GLP-1 approvals**: Comparable Lilly drug orforglipron was approved in the US in April 2026 (Wikipedia) — no filing-to-approval interval given, but tirzepatide/orforglipron precedents show standard multi-month-to-year FDA timelines post-filing; no evidence of unusually fast (<6 month) turnarounds for this drug class absent priority designation. 5. **Safety signals**: Dysesthesia signal noted at up to 20.9% at highest dose; common GI effects (diarrhea, nausea, constipation) across trials; Washington Post/Medscape note cardiovascular effects concerns with unregulated gray-market versions (not necessarily official trial data). No CRL or major delay-triggering signal reported for the sanctioned trials themselves (claude_news, GDELT). 6. **Earnings call guidance**: July 2026 Lilly quote (CNBC) explicitly states 2027 filing plan; earlier 2026 guidance (before July) had suggested late-2026 submission — this was superseded. Analyst commentary (Aug 2026) discusses retatrutide contributing to Lilly pipeline "over the course of '27 and '28," consistent with no 2026 approval (CNBC 2026-07-09/2026-08-05). # Key facts (high-confidence, factual) 1. [CNBC 2026-07-23] Lilly will file a BLA (not NDA) for retatrutide in Q1 2027, later than earlier 2026 guidance. 2. [CNBC/AJMC 2026-07-23] All five TRIUMPH Phase 3 trials have now reported positive toplines. 3. [retaweightloss.com] Standard FDA review = 10-12 months, priority = ~6 months; FDA priority-review decision undetermined. 4. [Wikipedia] Orforglipron (Lilly's oral GLP-1) was approved in the US April 2026, showing Lilly can get approvals but on its own filing timeline. 5. [Healio/Fool, Aug 2026] Retatrutide remains unapproved; Lilly suing black-market sellers and running an early-access (not FDA-approved) program. # Cross-market signals - Kalshi related: No direct retatrutide market found on Kalshi-related search; comparable FDA-approval markets (VERVE-102, MDMA-PTSD) trade 42-51%, reflecting genuine binary uncertainty for pending-but-filed drugs — not comparable given retatrutide hasn't even been filed. - Polymarket: 11.7% YES, uptrending +8.5%/+8.75% over 7d/30d despite confirmed filing delay to 2027 — likely driven by strong trial data optimism/momentum trading rather than updated regulatory-timeline logic. - Sportsbook implied: N/A. # Analyst opinions and speculation - TD Cowen estimates $3.8B 2030 sales for retatrutide — bullish on drug commercially but not signaling accelerated FDA timeline (CNBC). - Analysts (Gould, cited CNBC 2026-07-09) frame retatrutide's contribution as occurring "over the course of '27 and '28," implying no 2026 revenue/approval expectation. - BBC (2026-09-04): base rate of Phase III-to-approval success ~50%, underscoring approval is not guaranteed even eventually, independent of timing. # Directional lean per outcome - **Yes**: Weak. Requires either an unprecedented compressed review or acceptance/approval far ahead of Lilly's own Q1 2027 filing guidance — no evidence supports this. Positive trial data alone does not equal filing or approval. - **No**: Strong. Lilly explicitly confirmed (2026-07-23) it has not yet filed, and won't file until Q1 2027; FDA review (whether standard or priority) cannot plausibly complete an approval before Dec 31, 2026 since the clock hasn't started. # Gaps / unknowns - No confirmed Kalshi-direct YES price was returned in raw research (only Polymarket data available as proxy). - No information on whether Lilly has requested/received Priority Review Voucher or Breakthrough Therapy designation, which is the main variable that could theoretically alter (but not eliminate) the "No" case. - No detail on exact BLA filing progress/pre-submission meetings with FDA as of report date (Sept 2026). # Calibration anchors - Polymarket YES 11.7% (only cross-market data available; likely overpriced relative to structural facts). - Precedent: Orforglipron (Lilly) approved April 2026 after presumable ~1 year+ filing-to-approval cycle; typical FDA BLA/NDA review is 10-12 months standard, 6 months priority — filing not expected until Q1 2027 makes 2026 approval structurally near-impossible.

4. Forecasters Fable 5.1 + GPT-5.6 Sol · in parallel

claude-fable-5-1

86% conf

Yes	3%
No	97%

Lilly confirmed on 2026-07-23 that the retatrutide BLA will not be filed until Q1 2027, superseding earlier late-2026 guidance; since the FDA review clock has not started, even a ~6-month priority review cannot produce an approval before Dec 31, 2026. Analyst commentary frames retatrutide's contribution as arriving over 2027-2028, and no expedited designation or accelerated pathway has been reported. The Polymarket proxy at 11.7% appears driven by trial-data momentum rather than regulatory logic, and no Kalshi-direct price was available, so I deviate well below it toward the structural near-impossibility of a 2026 approval, leaving a small residual for a surprise early filing plus extraordinary FDA action or a resolution-mechanics quirk.

gpt-5.6-sol

91% conf

Yes	2%
No	98%

Positive TRIUMPH readouts support eventual approval but cannot produce a 2026 approval without a submitted application. Lilly’s superseding July guidance targets the BLA filing for Q1 2027, while even priority review typically takes about six months and no expedited status is confirmed. Safety findings do not appear prohibitive, but they also provide no mechanism for approval before filing, and analyst expectations place commercialization in 2027-2028. I therefore mark the 11.7% Polymarket YES anchor sharply downward because it conflicts with the documented regulatory timeline.

5. Devil's Advocate Sonnet 5 · red-team critique

Both forecasts converge tightly (0.025–0.03) without addressing why the market itself might have information they lack—e.g., neither considers whether "market creation" as literally stated in the Event definition (not Dec 31 close per the outcome resolution) could alter the window, or whether Lilly could file earlier than Q1 2027 given rolling-BLA/rolling-submission mechanics common for breakthrough biologics.

Neither forecaster explicitly addresses the "conditional approval" language in the outcome definition ("full or conditional, any indication")—rolling review or accelerated approval components could theoretically start before full BLA completion, and this nuance from the evidence brief's outcome wording is underexplored.

Both treat the Polymarket 11.7% as pure noise/momentum, but neither seriously entertains that the market may be pricing a small probability of resolution-source ambiguity (e.g., markets sometimes resolve YES on "approved for use" via early-access/expanded-access mechanisms that Lilly already launched in Aug 2026)—the brief notes an "early/pre-approval access program" that could create resolution ambiguity neither forecast flags as a scenario for miscoded YES.

Both forecasts are very close to each other (0.025 vs 0.030) suggesting insufficient independent uncertainty exploration—neither stress-tests the tail scenario of an unreported Priority Review Voucher or Breakthrough Therapy designation already in progress, despite the brief noting "Whether FDA will grant priority review has not yet been determined" as a live unknown rather than a resolved no.

Neither explicitly discounts for BBC's ~50% Phase III-to-approval base rate in a way that shows how it was weighed against the timeline argument—the timeline argument dominates, which is appropriate, but neither rationale explains why the safety signal (dysesthesia up to 20.9%) is fully dismissed as immaterial to any accelerated/emergency pathway.

Both forecasters anchor almost entirely on the Q1 2027 filing guidance without weighting the small-but-nonzero chance that Lilly's Q1 2027 language could itself be conservative/strategic (companies sometimes file earlier than guided), understating optionality on the upside case beyond a generic "surprise early filing" caveat.

6. Aggregator Fable 5.1 · final calibrated forecast

3% (88% confidence)

Yes: 3% No: 97%

Both forecasters drew the same, correct inference from the decisive sub-question: Lilly's superseding July 23, 2026 guidance places the BLA filing in Q1 2027, so the FDA review clock will not even start before the Dec 31, 2026 close, making approval structurally near-impossible regardless of standard, priority, or voucher-accelerated review. The critique's points are mostly weak—rolling submission still requires a complete application and review, the early-access program is explicitly not FDA approval, and 'conditional approval' still requires a filed and reviewed application—though they justify keeping a small residual for an unexpectedly early filing combined with an ultra-fast Commissioner's National Priority Voucher review or resolution-source ambiguity. The Polymarket 11.7% appears to reflect trial-data momentum rather than regulatory timeline logic, and no Kalshi anchor exists to override the documented facts. I settle at 3% Yes, in line with the consensus and slightly above the lower forecast to respect the tail scenarios flagged by the red team.

Pipeline Timing

Total pipeline time: 163.0s

Per-tool research timings shown in the Research section above.